Discovery of the GI Effects of GLP-1: An Historical Perspective

Research output: Contribution to journal › Review › Research › peer-review

Standard

Discovery of the GI Effects of GLP-1 : An Historical Perspective. / Holst, Jens Juul.

In: Digestive Diseases and Sciences, Vol. 67, 2022, p. 2716-2720.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Holst, JJ 2022, 'Discovery of the GI Effects of GLP-1: An Historical Perspective', Digestive Diseases and Sciences, vol. 67, pp. 2716-2720. https://doi.org/10.1007/s10620-022-07519-3

APA

Holst, J. J. (2022). Discovery of the GI Effects of GLP-1: An Historical Perspective. Digestive Diseases and Sciences, 67, 2716-2720. https://doi.org/10.1007/s10620-022-07519-3

Vancouver

Holst JJ. Discovery of the GI Effects of GLP-1: An Historical Perspective. Digestive Diseases and Sciences. 2022;67:2716-2720. https://doi.org/10.1007/s10620-022-07519-3

Author

Holst, Jens Juul. / Discovery of the GI Effects of GLP-1 : An Historical Perspective. In: Digestive Diseases and Sciences. 2022 ; Vol. 67. pp. 2716-2720.

Bibtex

@article{93c8456501584a169a2f957728ca0cce,
title = "Discovery of the GI Effects of GLP-1: An Historical Perspective",
abstract = "In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.",
keywords = "Enterogastrone, Gastric emptying, GLP-1RA, Ileal brake, Proglucagon",
author = "Holst, {Jens Juul}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2022",
doi = "10.1007/s10620-022-07519-3",
language = "English",
volume = "67",
pages = "2716--2720",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Discovery of the GI Effects of GLP-1

T2 - An Historical Perspective

AU - Holst, Jens Juul

N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2022

Y1 - 2022

N2 - In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.

AB - In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.

KW - Enterogastrone

KW - Gastric emptying

KW - GLP-1RA

KW - Ileal brake

KW - Proglucagon

U2 - 10.1007/s10620-022-07519-3

DO - 10.1007/s10620-022-07519-3

M3 - Review

C2 - 35635627

AN - SCOPUS:85131064063

VL - 67

SP - 2716

EP - 2720

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

ER -

ID: 310837857